Operator
I would now like to turn the call over to the CARA team. Please proceed.
Jack Hildick-Smith
Investor Relations
Good afternoon, this is Jack Hildick-Smith with Stern Investor Relations and welcome to Cara Therapeutics first quarter 2021 financial results and update conference call. The news release became available just after 4:00 PM today and can be found on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today s call on the Investors section of the website.
Before we begin, let me remind you that statements made on today s call regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements, include statements concerning the expected timing of the data readouts from the company s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regul
Good morning, and welcome to the Axsome Therapeutics Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Please go ahead.
Mark Jacobson
Chief Operating Officer
Thank you, operator. Good morning, and thank you all for joining us on today s conference call. Our earnings press release providing a corporate update and details of the company s financial results for the first quarter of 2021 crossed the wire a short time ago and is available on our website at axsome.com.
During today s call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct in the source of future clinical trials, regulatory plans, future research an
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Harmony Biosciences first-quarter 2021 financial update call. [Operator instructions] I would now like to hand the conference over to your host today, Lisa Caperelli, investor relations. Please go ahead.
Lisa Caperelli
Investor Relations
Thank you, operator. Good morning, everyone and thank you for joining us today as we review Harmony Biosciences first-quarter 2021 financial performance and provide business updates. Before we begin, I encourage everyone to go to the Investors section of the Harmony Biosciences website to find the press release and slides that accompany our presentation today, including a reconciliation of the GAAP to non-GAAP financial measures. At this stage of our company life cycle, we believe non-GAAP financial results better represent the underlying economics of our business.
Operator
Thank you for standing by. This is the conference operator. Welcome to the ZIOPHARM Oncology Inc s First Quarter 2021 Earnings Conference Call. As a reminder all participants are in a listen-only mode and the conference is being recorded. After the presentation there ll be an opportunity to ask questions [Operator Instructions].
I would now like to turn the conference over to Adam Levy, Executive Vice President, Investor Relations and Corporate Communications. Please go ahead.
Adam Levy
Executive Vice President, Investor Relations and Corporate Communications
Thank you, operator. Good afternoon and welcome to the ZIOPHARM Oncology conference call and webcast to review results for the first quarter ended March 31st, 2021. This afternoon we filed our 10-Q and issued our financial news release both of which are available in the Investors section of our website, ziopharm.com. For informational purposes, we have also posted a set of PowerPoint slides to accompany today s